The unfinished measles immunization agenda
- PMID: 12721885
- DOI: 10.1086/368226
The unfinished measles immunization agenda
Abstract
Despite achieving and sustaining global measles vaccination coverage of about 80% over the past decade, worldwide measles remains the fifth leading cause of mortality among children aged <5 years. In May 2002, the United Nations Special Session on Children endorsed the goal of reducing measles deaths by half by 2005. Countries and World Health Organization (WHO) regions that adopted aggressive measles control or elimination strategies have shown excellent results. In 2001, countries in the Americas reported an all time low of 537 confirmed measles cases. Substantial progress in measles control has also been achieved in the WHO Western Pacific Region, in seven southern African countries, and in selected countries in WHO European, Eastern Mediterranean, and Southeast Asian regions. The ongoing measles disease burden and availability of safe and effective measles mortality reduction strategies make a compelling case to complete the unfinished agenda of measles immunization.
Similar articles
-
Experience in global measles control, 1990-2001.J Infect Dis. 2003 May 15;187 Suppl 1:S15-21. doi: 10.1086/368273. J Infect Dis. 2003. PMID: 12721887
-
The challenge of achieving measles elimination in the eastern Mediterranean region by 2010.J Infect Dis. 2003 May 15;187 Suppl 1:S164-71. doi: 10.1086/368035. J Infect Dis. 2003. PMID: 12721909
-
Global measles control and regional elimination, 1998-1999.MMWR Morb Mortal Wkly Rep. 1999 Dec 17;48(49):1124-30. MMWR Morb Mortal Wkly Rep. 1999. PMID: 10634347
-
Progress toward measles eradication in the region of the Americas.J Infect Dis. 2003 May 15;187 Suppl 1:S102-10. doi: 10.1086/368032. J Infect Dis. 2003. PMID: 12721900 Review.
-
Evolution of measles elimination strategies in the United States.J Infect Dis. 2004 May 1;189 Suppl 1:S17-22. doi: 10.1086/377694. J Infect Dis. 2004. PMID: 15106084 Review.
Cited by
-
Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.Drugs. 2003;63(19):2107-26. doi: 10.2165/00003495-200363190-00012. Drugs. 2003. PMID: 12962524 Review.
-
Predictors for low coverage of uptake of second dose of measles vaccine among children in sub-Saharan Africa, 2023: a systematic review and meta-analysis.J Pharm Policy Pract. 2023 Dec 7;17(1):2285507. doi: 10.1080/20523211.2023.2285507. eCollection 2024. J Pharm Policy Pract. 2023. PMID: 38205190 Free PMC article. Review.
-
Sero-Prevalence Surveillance to Predict Vaccine-Preventable Disease Outbreaks; A Lesson from the 2014 Measles Epidemic in Northern Vietnam.Open Forum Infect Dis. 2019 Jan 24;6(3):ofz030. doi: 10.1093/ofid/ofz030. eCollection 2019 Mar. Open Forum Infect Dis. 2019. PMID: 30863786 Free PMC article.
-
Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.Drugs R D. 2016 Dec;16(4):327-338. doi: 10.1007/s40268-016-0144-x. Drugs R D. 2016. PMID: 27696306 Free PMC article.
-
Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles.Epidemiol Infect. 2012 Aug;140(8):1356-65. doi: 10.1017/S0950268811002032. Epub 2011 Oct 5. Epidemiol Infect. 2012. PMID: 22009033 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous